Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Theravance Biopharma (TBPH) today and set a price target of $55. The company’s shares opened today at $26.89.
Chen noted:
“We rate TBPH 12-month price target of $55. We believe the Street is underestimating the peak sales potential of its key programs (JAK Inhibitor, TD-9855, Revefenacin, among others) and preclinical assets. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $55. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $55.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 11.3% and a 42.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
Theravance Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $55.
See today’s analyst top recommended stocks >>
Based on Theravance Biopharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $59.43 million. In comparison, last year the company had a GAAP net loss of $86.92 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Theravance Biopharma, Inc. operates as a biopharmaceutical company, which focuses on the discovery, development and commercialization of small molecule medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
